公开(公告)号：US20230390211A1

公开(公告)日：2023-12-07

申请号：US18062252

申请日：2022-12-06

申请人： G&P BIOSCIENCE CO., LTD. ,  REYON PHARMACEUTICAL CO., LTD.

发明人： Seong-Hyun HO ,  Su Jin PARK

IPC分类号： A61K9/50 ,  A61P7/04 ,  A61K38/37 ,  A61P25/02 ,  A61K31/02 ,  A61K31/025 ,  A61K31/035 ,  A61K33/16 ,  A61K38/18 ,  A61K38/30 ,  A61K47/06 ,  A61K47/18 ,  A61K47/24 ,  A61K47/26 ,  A61K47/28

CPC分类号： A61K9/5015 ,  A61P7/04 ,  A61K38/37 ,  A61P25/02 ,  A61K31/02 ,  A61K31/025 ,  A61K31/035 ,  A61K33/16 ,  A61K38/1833 ,  A61K38/30 ,  A61K47/06 ,  A61K47/186 ,  A61K47/24 ,  A61K47/26 ,  A61K47/28 ,  A61K48/00

摘要： The present disclosure relates to a composition for increasing the expression of a blood coagulation factor gene, which contains core-shell structured microparticles as an active ingredient. When administered in vivo along with blood coagulation factor VIII gene or a variant gene thereof, the composition for increasing the expression of a blood coagulation factor gene of the present disclosure can increase the expression of the gene by at least 30%. When administered along with a gene therapeutic agent, the composition can achieve a therapeutic effect even with a very small amount of a gene, and thus is useful.

公开(公告)号：US11723762B2

公开(公告)日：2023-08-15

申请号：US15420366

申请日：2017-01-31

申请人： Velodyne Lidar, Inc.

发明人： David S. Hall ,  Mathew Noel Rekow ,  Pieter J. Kerstens

IPC分类号： G01S7/48 ,  A61C19/06 ,  G01S7/481 ,  G01S7/487 ,  G01S17/89 ,  G01S17/10 ,  G01C3/08 ,  G01S17/931 ,  A61P1/02 ,  A61K9/00 ,  A61K31/025 ,  A61K31/075 ,  A61K31/164 ,  A61K31/198 ,  A61K31/205 ,  A61K31/355 ,  A61K31/714 ,  A61K31/728 ,  A61K36/28 ,  A61K36/48 ,  A61K36/52 ,  A61K36/63 ,  A61K36/736 ,  A61K36/752 ,  A61K36/81

CPC分类号： A61C19/063 ,  A61K9/0053 ,  A61K31/025 ,  A61K31/075 ,  A61K31/164 ,  A61K31/198 ,  A61K31/205 ,  A61K31/355 ,  A61K31/714 ,  A61K31/728 ,  A61K36/28 ,  A61K36/48 ,  A61K36/52 ,  A61K36/63 ,  A61K36/736 ,  A61K36/752 ,  A61K36/81 ,  A61P1/02 ,  G01C3/08 ,  G01S7/487 ,  G01S7/4811 ,  G01S7/4815 ,  G01S7/4817 ,  G01S17/10 ,  G01S17/89 ,  G01S17/931

摘要： Methods and systems for performing 3-D LIDAR measurements of objects simultaneously illuminated by two or more beams of light in the far field are described herein. A 3-D LIDAR based measurement device simultaneously emits at least two beams of light into a three dimensional environment from different locations. A portion of the three dimensional environment is simultaneously illuminated by the two or more light beams at a distance of at least five meters from the LIDAR device. However, the two or more light beams do not overlap at a distance less than five meters from the LIDAR device. The beams of light are slightly divergent, having highest intensity at the device and steadily lower intensity further away. By overlapping illumination beams in the far field, but not near the LIDAR device, overall intensity is maintained at moderate levels throughout the field of view of the LIDAR device.

公开(公告)号：US20220233489A1

公开(公告)日：2022-07-28

申请号：US17587307

申请日：2022-01-28

申请人： ChemistryRX

发明人： Amany Mansour-Awad ,  Lars Brichta

IPC分类号： A61K31/203 ,  A61K8/67 ,  A61K9/00 ,  A61Q19/08 ,  A61K31/07 ,  A61K31/11 ,  A61K31/025 ,  A61K31/216 ,  A61K31/728 ,  A61K31/455 ,  A61K31/197

摘要： Compositions and methods for treating administering retinoid or retinoid-related compounds without side effects.

公开(公告)号：US10570090B2

公开(公告)日：2020-02-25

申请号：US15613689

申请日：2017-06-05

申请人： SANOFI

发明人： Monsif Bouaboula ,  Maurice Brollo ,  Victor Certal ,  Youssef El-Ahmad ,  Bruno Filoche-Romme ,  Frank Halley ,  Gary McCort ,  Laurent Schio ,  Michel Tabart ,  Corinne Terrier ,  Fabienne Thompson

IPC分类号： A61K31/40 ,  A61K31/025 ,  C07C13/32 ,  C07C22/08 ,  C07D207/12 ,  C07D403/12 ,  C07D401/12 ,  C07D471/04 ,  C07D405/12 ,  C07D413/12 ,  C07F7/08 ,  C07D417/12 ,  C07F5/02

摘要： Compounds of formula (I): wherein R1 and R2 represent hydrogen or deuterium atoms; R3 represents a hydrogen atom or a —COOH, a —OH or a —OPO(OH)2 group; R4 represents a hydrogen atom or a fluorine atom; R5 represents a hydrogen atom or a —OH group; wherein at least one of R3 or R5 is different from a hydrogen atom; when R3 represents a —COOH, —OH or —OPO(OH)2 group, then R5 represents a hydrogen atom; when R5 represents a —OH group, then R3 and R4 represent hydrogen atoms; and R6 is selected from an optionally substituted phenyl, heteroaryl, cycloalkyl and heterocycloalkyl group; and the preparation and the therapeutic uses of the compounds of formula (I) as inhibitors and degraders of estrogen receptors, useful especially in the treatment of cancer.

公开(公告)号：US20190083220A1

公开(公告)日：2019-03-21

申请号：US16196872

申请日：2018-11-20

申请人： 3M INNOVATIVE PROPERTIES COMPANY

发明人： Katie F. Wlaschin ,  Amanda C. Engler ,  Hannah C. Cohen ,  Yizhong Wang ,  Tao Gong ,  Tiffany T. Ton ,  Joel D. Oxman ,  Jie Yang ,  Richard P. Rusin

IPC分类号： A61C19/06 ,  A61P1/02 ,  A61K9/00 ,  A61K31/355 ,  A61K31/714 ,  A61K31/198 ,  A61K31/728 ,  A61K31/164 ,  A61K31/205 ,  A61K36/28 ,  A61K36/48 ,  A61K36/52 ,  A61K36/81 ,  A61K36/736 ,  A61K36/752 ,  A61K36/63 ,  A61K31/025 ,  A61K31/075

摘要： Compositions that include: from 5 wt-% to 30 wt-% of one or more plant based oils based on the total weight of the composition; from 70 wt-% to 95 wt-% of an aqueous phase based on the total weight of the composition; from 0.1 wt-% to 5 wt-% of one or more surfactants based on the total weight of the composition; and from 0.05 wt-% to 3 wt-% of a viscosity modifier, wherein the composition has a pH from 4.5 to 9.5, the composition is an oil in water (o/w) emulsion, and the composition is edible. Methods of utilizing disclosed compositions are also included.

公开(公告)号：US10010525B2

公开(公告)日：2018-07-03

申请号：US15788034

申请日：2017-10-19

申请人： The Regents of the University of California

发明人： Robert J. Brosnan

IPC分类号： A61K31/025 ,  A61M16/01 ,  A61D7/04 ,  A61K31/351 ,  A61K31/08 ,  A61K31/02 ,  A61K31/045 ,  A61K31/357 ,  A61K31/341 ,  A61K9/00

CPC分类号： A61K31/351 ,  A61D7/04 ,  A61K9/007 ,  A61K31/02 ,  A61K31/025 ,  A61K31/045 ,  A61K31/08 ,  A61K31/341 ,  A61K31/357 ,  A61M16/01

摘要： The present invention provides methods for determining the selectivity of an anesthetic for an anesthetic-sensitive receptor by determining the molar water solubility of the anesthetic. The invention further provides methods for modulating the selectivity of an anesthetic for an anesthetic-sensitive receptor by altering or modifying the anesthetic to have higher or lower water solubility. The invention further provides methods of inducing anesthesia in a subject by administering via the respiratory pathways (e.g., via inhalational or pulmonary delivery) an effective amount of an anesthetic compound identified according to the present methods.

公开(公告)号：US20160228380A1

公开(公告)日：2016-08-11

申请号：US15023619

申请日：2014-09-23

申请人： VIRGINIA COMMONWEALTH UNIVERSITY

发明人： Mark A. McHugh ,  Rajendar Reddy Mallepally ,  Kevin R. Ward ,  Gary S. Huvard

IPC分类号： A61K9/70 ,  A61K47/38 ,  A61L15/28 ,  A61L15/18 ,  A61K9/06 ,  A61L15/44 ,  A61K31/025 ,  A61K47/02 ,  A61K45/06 ,  A61K33/40 ,  A61L15/42

CPC分类号： A61K9/7007 ,  A61K9/06 ,  A61K9/5026 ,  A61K31/025 ,  A61K31/327 ,  A61K33/40 ,  A61K45/06 ,  A61K47/02 ,  A61K47/38 ,  A61L15/18 ,  A61L15/26 ,  A61L15/28 ,  A61L15/425 ,  A61L15/44 ,  A61L2300/106 ,  A61L2300/11 ,  C08L83/04 ,  A61K2300/00

摘要： Oxygen carrier compounds are impregnated into carrier materials that have free volume, empty or void space or high porosity using sub or supercritical fluid assisted processing. Compositions and methods for the treatment of wounds and burns are provided comprising peroxide compounds or perfluorinated compounds impregnated into carrier materials applied directly to the wound or burn.

摘要翻译： 氧载体化合物被浸渍到具有自由体积，空或空隙空间或使用亚临界或超临界流体辅助处理的高孔隙率的载体材料中。 提供了用于治疗伤口和烧伤的组合物和方法，其包括浸渍到直接施加于伤口或烧伤的载体材料中的过氧化物化合物或全氟化合物。

公开(公告)号：US09402817B2

公开(公告)日：2016-08-02

申请号：US14832398

申请日：2015-08-21

申请人： Michael P. O'Neil

发明人： Michael P. O'Neil

IPC分类号： A61K33/24 ,  A61K47/02 ,  A61K47/14 ,  A61K47/26 ,  A61K47/38 ,  A61K31/025 ,  A61F13/40 ,  A61N5/06 ,  A61Q19/00 ,  A61B18/20 ,  A61Q1/14 ,  A61K8/70 ,  A61K41/00 ,  A61B18/00 ,  A61B17/00

CPC分类号： A61K8/70 ,  A61B18/203 ,  A61B2017/00769 ,  A61B2018/00458 ,  A61B2018/0047 ,  A61B2018/00577 ,  A61K8/0208 ,  A61K31/025 ,  A61K41/00 ,  A61K2800/81 ,  A61M35/006 ,  A61N5/0616 ,  A61N5/062 ,  A61Q1/145 ,  A61Q19/00

摘要： A treatment system and method includes use of a chemical facilitator to provide a result-effective event against one or more negative therapeutic effects related to exposing to a light output a skin portion including a condition treatable in whole or in part with light. In one exemplary embodiment for skin treatment including tattoo removal, perfluorodecalin is used to inhibit or resolve whitening, for example to speed a laser therapy session.

公开(公告)号：US09144554B2

公开(公告)日：2015-09-29

申请号：US14588480

申请日：2015-01-02

申请人： Carmelo Cutrupi

发明人： Carmelo Cutrupi

IPC分类号： A61K31/025 ,  A61K9/00 ,  A61K31/695 ,  A61K31/185 ,  A61K31/035 ,  A61K31/192

CPC分类号： A61K31/025 ,  A61K9/0014 ,  A61K31/035 ,  A61K31/185 ,  A61K31/192 ,  A61K31/695

摘要： The present invention relates to the use of topical compositions containing bromociclen for the prevention and/or treatment of various types of dermatitis, in particular eczema and psoriasis.

摘要翻译： 本发明涉及包含溴隐球菌的局部组合物用于预防和/或治疗各种类型的皮炎，特别是湿疹和牛皮癣的用途。

公开(公告)号：US08822549B2

公开(公告)日：2014-09-02

申请号：US13273115

申请日：2011-10-13

申请人： Jennifer L. Johnson ,  Evan C. Unger

发明人： Jennifer L. Johnson ,  Evan C. Unger

IPC分类号： A61K31/02 ,  A61K31/7016 ,  A61K47/26 ,  A61K9/107 ,  A61K31/685 ,  A61K47/10 ,  A61K31/03 ,  A61K9/00 ,  A61K31/025

CPC分类号： A61K9/0026 ,  A61K31/02 ,  A61K31/025 ,  A61K31/03 ,  A61K31/685 ,  A61K31/7016 ,  A61K47/10 ,  A61K47/26

摘要： An oxygen therapeutic composition, comprising a perfluorocarbon material, a viscosity modifier, a buffer, wherein the buffer stabilizes a pH of the composition at between about 6.5 to about 7.5, and wherein the composition comprises a viscosity of about 2.0 to about 3.5 mPas, and wherein the fluorocarbon has a boiling point of about 4 degrees Celsius to about 60 degrees Celsius.

摘要翻译： 一种氧治疗组合物，其包含全氟化碳材料，粘度调节剂，缓冲剂，其中所述缓冲液将所述组合物的pH稳定在约6.5至约7.5之间，并且其中所述组合物包含约2.0至约3.5mPas的粘度，以及 其中所述碳氟化合物的沸点为约4摄氏度至约60摄氏度。